Pharmaceutical Executive
Pharmaceutical Executive
Pharmaceutical Executive Podcast
Pharmaceutical Executive Daily: Nxera Licenses EP4 Agonist to AbbVie
2 minutes Posted Nov 4, 2026 at 8:34 pm.
0:00
2:45
Download MP3
Show notes
How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion oncology licensing deal with Sino Biopharmaceutical and Nxera Pharma’s EP4 agonist deal with AbbVie, and CytoDyn’s Dr. Jay Lalezari on why Leronlimab isn’t just another repurposed drug.